Core Viewpoint - B. Riley analyst Sean-Paul Adams has raised the price target for Gladstone Investment (GAIN) to $14.50 from $14 while maintaining a Neutral rating on the shares [1] Summary by Category Price Target Adjustment - The price target for Gladstone Investment has been increased to $14.50 from $14 [1] Analyst Rating - B. Riley continues to hold a Neutral rating on Gladstone Investment shares [1] Model Adjustment - The firm's model for Gladstone Investment was adjusted following the fiscal Q3 report [1]

Core Viewpoint - Bank of America has raised the price target for Yum! Brands (YUM) to $178 from $173 while maintaining a Neutral rating on the shares [1] Financial Estimates - Following the Q4 results, the firm's estimates have been slightly adjusted downwards due to higher expenses associated with Pizza Hut [1] - Despite the downward adjustment in estimates, the price target has increased slightly due to market multiple expansion [1]

Core Viewpoint - TD Cowen analyst Oliver Chen has lowered the price target on Elf Beauty (ELF) to $100 from $110 while maintaining a Buy rating on the shares [1] Group 1: Price Target Adjustment - The price target for Elf Beauty has been reduced to $100 from $110 [1] - The firm updated its estimates following Q3 results [1] Group 2: Growth Expectations - Core growth is expected to normalize to low single digits (LSD%) in the second half of the year [1] - This normalization may keep shares range-bound in the near term [1]

Group 1 - RBC Capital raised the price target on nVent Electric (NVT) to $138 from $136 while maintaining an Outperform rating on the shares after the company's Q4 earnings [1] - The datacenter growth story for nVent remains fully on track according to the in-line Q4 operating results and the 2026 guidance provided by the company [1] - Investor excitement was somewhat dampened due to softer margins resulting from transitory capacity ramp costs, as noted by the analyst in a research note [1]

Core Viewpoint - Morgan Stanley analyst Josh Baer has lowered the price target for Lightspeed (LSPD) to $13.50 from $15 while maintaining an Equal Weight rating on the shares, indicating a cautious outlook on the stock's performance [1]. Financial Performance - The Q3 results for Lightspeed showed evidence of yield on transition and investments towards growth engine markets, suggesting potential for future growth despite the lowered price target [1].

Core Viewpoint - Morgan Stanley has lowered the price target for News Corp. (NWSA) to $32.40 from $38 while maintaining an Overweight rating on the shares, indicating a positive outlook despite the adjustment in price target [1] Group 1: Price Target Adjustment - The price target for News Corp. has been reduced from $38 to $32.40 [1] - The adjustment follows the release of the first half of FY26 results [1] Group 2: Rating and Thesis - Morgan Stanley retains an Overweight rating on News Corp. shares [1] - There is no change to the firm's "fundamental positive thesis" regarding News Corp. [1]

Group 1 - Morgan Stanley raised the price target on Linde (LIN) to $530 from $495, maintaining an Overweight rating on the shares [1] - The operating environment remains challenging, but Linde is expected to show better growth in 2026 compared to 2025 due to fewer and less intense headwinds [1] - Factors contributing to Linde's anticipated growth include increased productivity, benefits from project startups and bolt-on acquisitions, foreign exchange tailwinds, and potential macroeconomic improvements as the year progresses [1]

Core Viewpoint - Morgan Stanley analyst Terence Flynn has raised the price target for Bristol Myers (BMY) to $40 from $37 while maintaining an Underweight rating on the shares [1] Revenue and EPS Guidance - The 2026 revenue and EPS guidance for Bristol Myers came in above consensus expectations [1] - This positive outlook was primarily driven by a higher than expected guidance for Eliquis [1]

Group 1 - Morgan Stanley raised the price target on Cardinal Health (CAH) to $255 from $245 [1] - The firm maintains an Overweight rating on Cardinal Health shares [1] - The updated risk-reward profile follows the company's strong Q2 results [1]

Group 1 - Morgan Stanley raised the price target on Crown Holdings (CCK) to $134 from $129 [1] - The firm maintains an Overweight rating on Crown Holdings shares [1] - The revision of estimates followed the Q4 reporting of Crown Holdings [1]